This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Mar 15;205(6):608-610.

doi: 10.1164/rccm.202111-2587ED.

FocuSSced on the Target in Systemic Sclerosis-Interstitial Lung Disease: Another Arrow in the Quiver?

Scott M Matson¹, Melissa Griffith², Joyce S Lee²

Affiliations

Affiliations

¹ Department of Medicine University of Kansas School of Medicine Kansas City, Kansas.
² Department of Medicine University of Colorado School of Medicine Aurora, Colorado.

PMID: 34905698
DOI: 10.1164/rccm.202111-2587ED

Editorial

FocuSSced on the Target in Systemic Sclerosis-Interstitial Lung Disease: Another Arrow in the Quiver?

Scott M Matson et al. Am J Respir Crit Care Med. 2022.

. 2022 Mar 15;205(6):608-610.

doi: 10.1164/rccm.202111-2587ED.

Authors

Scott M Matson¹, Melissa Griffith², Joyce S Lee²

Affiliations

¹ Department of Medicine University of Kansas School of Medicine Kansas City, Kansas.
² Department of Medicine University of Colorado School of Medicine Aurora, Colorado.

PMID: 34905698
DOI: 10.1164/rccm.202111-2587ED

No abstract available

PubMed Disclaimer

Comment on

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. Khanna D, et al. Am J Respir Crit Care Med. 2022 Mar 15;205(6):674-684. doi: 10.1164/rccm.202103-0714OC. Am J Respir Crit Care Med. 2022. PMID: 34851799 Clinical Trial.

Similar articles

Interstitial lung disease in scleroderma.
Schoenfeld SR, Castelino FV. Schoenfeld SR, et al. Rheum Dis Clin North Am. 2015 May;41(2):237-48. doi: 10.1016/j.rdc.2014.12.005. Epub 2015 Feb 26. Rheum Dis Clin North Am. 2015. PMID: 25836640 Free PMC article. Review.
Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.
Takahashi T, Asano Y, Sunaga R, Ichimura Y, Taniguchi T, Yamamoto M, Tamaki Z, Takekoshi T, Mitsui H, Sugaya M, Ohse T, Sato S. Takahashi T, et al. J Dermatol. 2014 Jun;41(6):533-5. doi: 10.1111/1346-8138.12495. Epub 2014 May 10. J Dermatol. 2014. PMID: 24814462
[Interstitial pneumonitis as a clinical manifestation in a patient with systemic sclerosis without scleroderma].
Cubo Romano P, Mínguez García P, Muñoz Albarrán S, Abad Cardiel M, Pontes Navarro JC. Cubo Romano P, et al. An Med Interna. 2005 Aug;22(8):402-3. doi: 10.4321/s0212-71992005000800019. An Med Interna. 2005. PMID: 16358436 Spanish. No abstract available.
[Diffuse interstitial pneumonia revealing systemic sclerosis sine scleroderma].
Baili L, Aydi Z, Rachdi I, Ben Dhaou B, Boussema F, Rokbani L. Baili L, et al. Tunis Med. 2014 Jul;92(7):508-10. Tunis Med. 2014. PMID: 25775296 French. No abstract available.
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann ER, Tashkin DP. Volkmann ER, et al. Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR. Ann Am Thorac Soc. 2016. PMID: 27560196 Free PMC article. Review.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Grants and funding

P20 GM130423/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information